TN2015000236A1 - Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis - Google Patents

Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis

Info

Publication number
TN2015000236A1
TN2015000236A1 TNP2015000236A TN2015000236A TN2015000236A1 TN 2015000236 A1 TN2015000236 A1 TN 2015000236A1 TN P2015000236 A TNP2015000236 A TN P2015000236A TN 2015000236 A TN2015000236 A TN 2015000236A TN 2015000236 A1 TN2015000236 A1 TN 2015000236A1
Authority
TN
Tunisia
Prior art keywords
dimethylpropan
carboxy
ethyl
aminium
pharmaceutically acceptable
Prior art date
Application number
TNP2015000236A
Other languages
English (en)
Inventor
Ivars Kalvins
Edgars Liepins
Einars Loza
Maija Dambrova
Ilmars Stonans
Daina Lola
Janis Kuka
Osvalds Pugovics
Reinis Vilskersts
Solveiga Grinberga
Viktors Andrianovs
Daina Gustina
Marina Makrecka
Original Assignee
Grindeks Jsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks Jsc filed Critical Grindeks Jsc
Publication of TN2015000236A1 publication Critical patent/TN2015000236A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TNP2015000236A 2012-12-20 2015-06-01 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis TN2015000236A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12198627 2012-12-20
PCT/EP2013/077291 WO2014096133A1 (fr) 2012-12-20 2013-12-19 Utilisation du 3-carboxy-n-éthyl-n,n-diméthylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable pour le traitement de l'athérosclérose

Publications (1)

Publication Number Publication Date
TN2015000236A1 true TN2015000236A1 (en) 2016-10-03

Family

ID=47458734

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000236A TN2015000236A1 (en) 2012-12-20 2015-06-01 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis

Country Status (11)

Country Link
CN (1) CN104869988B (fr)
AR (1) AR094084A1 (fr)
BR (1) BR112015014161B1 (fr)
CA (1) CA2895574C (fr)
CU (1) CU20150067A7 (fr)
JO (1) JO3117B1 (fr)
MX (1) MX362762B (fr)
PE (1) PE20151587A1 (fr)
TN (1) TN2015000236A1 (fr)
WO (1) WO2014096133A1 (fr)
ZA (1) ZA201505093B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1009600A2 (fr) * 2009-06-25 2016-03-22 Tetra S A
WO2010149654A1 (fr) * 2009-06-25 2010-12-29 Grindeks, A Joint Stock Company Composition pharmaceutique de gamma-butyrobétaïne ou sel pharmaceutiquement acceptable et de meldonium ou sel pharmaceutiquement acceptable
LV14345B (lv) * 2009-10-22 2011-07-20 Grindeks, A/S 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai
RS55092B1 (sr) * 2011-04-27 2016-12-30 Grindeks Jsc Upotreba 3-karboksi-n-etil-n,n-dimetilpropan-1-aminijum soli u lečenju kardiovaskularne bolesti

Also Published As

Publication number Publication date
MX362762B (es) 2019-02-06
CN104869988A (zh) 2015-08-26
JO3117B1 (ar) 2017-09-20
BR112015014161B1 (pt) 2021-02-17
AR094084A1 (es) 2015-07-08
CU20150067A7 (es) 2016-01-29
BR112015014161A2 (pt) 2017-07-11
MX2015008138A (es) 2016-04-25
PE20151587A1 (es) 2015-12-05
CA2895574C (fr) 2019-11-26
CA2895574A1 (fr) 2014-06-26
CN104869988B (zh) 2017-07-28
WO2014096133A1 (fr) 2014-06-26
ZA201505093B (en) 2016-04-28

Similar Documents

Publication Publication Date Title
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
MY166936A (en) Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
IN2015DN00895A (fr)
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
IN2015DN01156A (fr)
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
PT2848097T (pt) Dispositivo para o tratamento de plasma de superfícies humanas, animais ou de plantas, em particular da pele ou de áreas de membrana mucosa
IN2014DN10670A (fr)
TW201144301A (en) Processes for preparing linezolid
AU336556S (en) Laser system for treatment of the eye
AU348056S (en) Fitting for an air treatment chemical dispenser
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
AU336555S (en) Laser system for treatment of the eye
MX364220B (es) Metodos de tratamientos de fibrosis.
HK1203054A1 (en) Dinuceloside polyphosphates for the treatment of pain
AU341326S (en) Sofa ensemble
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
IN2013MU01111A (fr)
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles